Mark Lackner - Zentalis Pharmaceuticals Chief Strategy
| ZNTL Stock | USD 3.50 0.27 8.36% |
Insider
Mark Lackner is Chief Strategy of Zentalis Pharmaceuticals Llc
| Age | 56 |
| Address | 1359 Broadway, New York, NY, United States, 10018 |
| Phone | 212 433 3791 |
| Web | https://zentalis.com |
Zentalis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2524) % which means that it has lost $0.2524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4289) %, meaning that it created substantial loss on money invested by shareholders. Zentalis Pharmaceuticals' management efficiency ratios could be used to measure how well Zentalis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.56. The value of Return On Capital Employed is expected to slide to -0.54. At this time, Zentalis Pharmaceuticals' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 10 M this year, although the value of Non Current Assets Total will most likely fall to about 54.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthew MBA | Iteos Therapeutics | 51 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Joanne MD | Iteos Therapeutics | 52 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Margaret JD | Revolution Medicines | 61 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Ryan Baker | Iteos Therapeutics | N/A | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| Esq JD | Annexon | 56 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Kevin Dushney | Kymera Therapeutics | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Michael Fischbach | Revolution Medicines | 43 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 |
Zentalis Pharmaceuticals Leadership Team
Elected by the shareholders, the Zentalis Pharmaceuticals' board of directors comprises two types of representatives: Zentalis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zentalis. The board's role is to monitor Zentalis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zentalis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zentalis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Bunker, CoFounder Officer | ||
| Carrie MD, Chief Officer | ||
| Adrian MD, Executive Development | ||
| Mark Lackner, Chief Strategy | ||
| Ingmar MD, Chief Officer | ||
| Vincent Vultaggio, VP Officer | ||
| Kimberly Freeman, Chief Officer | ||
| Cameron MBA, President, CoFounder | ||
| Adam Levy, VP Relations | ||
| Melissa MBA, CFO Treasurer | ||
| Kimberly MD, CEO Director | ||
| Andrea JD, General Secretary | ||
| Diana MD, Chief Director | ||
| Julie MBA, President CEO | ||
| PharmD Rasbach, Chief Officer | ||
| Meena Rao, VP Assurance |
Zentalis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zentalis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (5.16) % | ||||
| Current Valuation | (120.61 M) | ||||
| Shares Outstanding | 71.27 M | ||||
| Shares Owned By Insiders | 3.83 % | ||||
| Shares Owned By Institutions | 98.05 % | ||||
| Number Of Shares Shorted | 7.05 M | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 5.68 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.